Restaging of differentiated thyroid carcinoma with SPECT/CT after radioiodine therapy
https://doi.org/10.14341/ket2015317-23
Abstract
Purpose.
The purpose of the study was to assess the diagnostic value of SPECT/CT data after radioiodine therapy in comparison with the data of soft tissue neck ultrasonography (US) and computed tomography (CT) in patients with differentiated thyroid carcinoma (DTC) and thus to investigate the role of SPECT/CT data in the restaging of DTC.
Material and methods.
We analyzed the results of 263 patients who were examined from November 2011 to April 2014, at the age of 10 to 78 years (190 female and 73 male). According to postoperative histological tests, 255 patients had papillary thyroid cancer and 38 patients had follicular thyroid cancer. Soft tissue neck US, CT of the chest without intravenous contrast and scintigraphy with 99mTc-pertechnetate in all patients were performed and then they were treated with radioiodine (dose, 3.0–5.5 GBq). Whole-body scintigraphy (WBS) and SPECT/CT were performed on the 3–5 day in all patients receiving radioiodine therapy.
Results.
After radioiodine therapy and SPECT/CT cancer stage diagnosed with US, CT, and scintigraphy was changed to N in 36.7% of patients, and cancer stage was changed to M in 11% of patients. The frequency of regio-nal cervical metastasis not detectable with US but suspected on WBS was 43.9%. In most cases, there were micrometastasis and lymph node metastases in the pre- and paratracheal areas, which were difficult to access by US.
Conclusion.
SPECT/CT after radioiodine therapy could improve the assessment of cancer stage and prognosis in patients with DTC.
About the Authors
Mariya Alekseevna Karalkina
Russian Scientific Center of Roentgeno-Radiology
Russian Federation
MD
Russian Federation
MD
Elena Igorevna Vasilenko
Russian Scientific Center of Roentgeno-Radiology
Russian Federation
MD
Russian Federation
MD
Dmitriy Kirillovich Fomin
Russian Scientific Center of Roentgeno-Radiology
Russian Federation
MD, PhD
Russian Federation
MD, PhD
Dmitriy Anatol'evich Galushko
Russian Scientific Center of Roentgeno-Radiology
Russian Federation
MD, PhD
Russian Federation
MD, PhD
References
1. Mustafa M, Kuwert T, Weber K, et al. Regional lymph node involvement in t1 papillary thyroid carcinoma: A bicentric prospective spect/ct study. Eur J Nucl Med Mol Imaging. 2010;37(8):1462-1466. doi: 10.1007/s00259-010-1408-2.
2. Румянцев П.О., Ильин А.А., Румянцева У.Ф., Саенко В.А. Рак щитовидной железы. Современные подходы к диагностике и лечению. – М.: ГЭОТАР-Медиа; 2009. [Rumyantsev PO, Il’in AA, Rumyantseva UF, Saenko VA. Rak shchitovidnoi zhelezy. Sovremennye podkhody k diagnostike i lecheniyu. Moscow: GEOTAR-Media; 2009. (In Russ).]
3. Состояние онкологической помощи населению России в 2012 году. / Под ред. Каприна А.Д., Старинского В.В., Петровой Г.В. – М.: ФГБУ “МНИОИ им. П.А. Герцена” Минздрава России; 2013. [Sostoyanie onkologicheskoy pomoshchi naseleniyu Rossii v 2012 godu. Ed. by Kaprin AD, Starinskiy VV, Petrova GV. Moscow; 2013. (In Russ).]
4. Gallicchio R, Giacomobono S, Capacchione D, et al. Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation? Endocrine. 2013;44(2):426-433. doi: 10.1007/s12020-013-9935-9.
5. Shimamoto K, Satake H, Sawaki A, et al. Preoperative staging of thyroid papillary carcinoma with ultrasonography. Eur J Radiol. 1998;29(1):4-10. doi: 10.1016/s0720-048x(97)00184-8.
6. Spanu A, Solinas ME, Chessa F, et al. 131i spect/ct in the follow-up of differentiated thyroid carcinoma: Incremental value versus planar imaging. J Nucl Med. 2009;50(2):184-190. doi: 10.2967/jnumed.108.056572.
7. Xue Y-L, Qiu Z-L, Song H-J, et al. Value of 131i spect/ct for the evaluation of differentiated thyroid cancer: A systematic review of the literature. Eur J Nucl Med Mol Imaging. 2012;40(5):768-778. doi: 10.1007/s00259-012-2310-x.
8. Sherma SI. Thyroid carcinoma. Lancet. 2003;361(9356):501-511. doi: 10.1016/s0140-6736(03)12488-9.
9. Tharp K, Israel O, Hausmann J, et al. Impact of 131i-spect/ct images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2004;31(10). doi: 10.1007/s00259-004-1565-2.
10. Chen L, Luo Q, Shen Y, et al. Incremental value of 131i spect/ct in the management of patients with differentiated thyroid carcinoma. J Nucl Med. 2008;49(12):1952-1957. doi: 10.2967/jnumed.108.052399.
11. Schmidt D, Szikszai A, Linke R, et al. Impact of 131i spect/spiral ct on nodal staging of differentiated thyroid carcinoma at the first radioablation. J Nucl Med. 2008;50(1):18-23. doi: 10.2967/jnumed.108.052746.
12. Kohlfuerst S, Igerc I, Lobnig M, et al. Posttherapeutic 131i spect-ct offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen. Eur J Nucl Med Mol Imaging. 2009;36(6):886-893. doi: 10.1007/s00259-008-1044-2.
13. Wang H, Fu H-L, Li J-N, et al. The role of single-photon emission computed tomography/computed tomography for precise localization of metastases in patients with differentiated thyroid cancer. Clin Imaging. 2009;33(1):49-54. doi: 10.1016/j.clinimag.2008.06.024.
14. Солодкий В.А., Фомин Д.К., Галушко Д.А., и др. Гибридное исследование всего тела (ОФЭКТ-КТ) после радио-йод-терапии, влияние на дальнейшую тактику лечения. // Вестник Российского научного центра рентгенорадиологии Минздрава России. – 2013. – Т.3. – №13. [Solodkii VA, Fomin DK, Galushko DA, et al. Gibridnoe issledovanie vsego tela (OFEKT-KT) posle radioiodterapii, vliyanie na dal’neishuyu taktiku lecheniya. Vestnik Rossiiskogo nauchnogo tsentra rentgenoradiologii Minzdrava Rossii. 2013;3(13). (In Russ).]
15. Фомин Д.К., Люгай О.О., Тарарухина О.Б. Совмещенное ОФЭКТ-КТ исследование в оценке распространенности заболевания и определении дальнейшей тактики лечения больных раком щитовидной железы. // Вестник Российского научного центра рентгенорадиологии Минздрава России. – 2012. – Т. 4. – №12. [Fomin DK, Lyugai OO, Tararukhina OB. Sovmeshchennoe OFEKT-KT issledovanie v otsenke rasprostranennosti zabolevaniya i opredelenii dal’neishei taktiki lecheniya bol’nykh rakom shchitovidnoi zhelezy. Vestnik Rossiyskogo nauchnogo tsentra rentgenoradiologii Minzdrava Rossii. 2012;4(12). (In Russ).]
16. Цыб А.Ф., Древаль А.В., Гарбузов П.И. Радиойодтерапия тиреотоксикоза. Руководство. – М.: ГЭОТАР-Медиа; 2009. [Tsyb AF, Dreval’ AV, Garbuzov PI. Radioiodterapiya tireotoksikoza. Rukovodstvo. Moscow: GEOTAR-Media; 2009. (In Russ).]
17. Pacini F, Castagna MG, Brilli L, et al. Thyroid cancer: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):VII110-VII119. doi: 10.1093/annonc/mds230.
18. Бубнов А.Н. О европейском консенсусе по диагностике и лечению дифференцированного рака щитовидной железы из фолликулярного эпителия и реализация его рекомендаций в наших условиях, дискуссия. // Клиническая и эксперимен-тальная тиреоидология. – 2007. – Т.3. – №3 – С. 9–11. [Bubnov AN. About european consensus in diagnostics and treatment of differentiated thiroid cancer and theyr implemeutation in our conditious. Clinical and experimental thyroidology. 2007;3(3):9. (In Russ).] doi: 10.14341/ket2007339-11.
19. Van Nostrand D, Aiken M, Atkins F, et al. The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer. Thyroid. 2009;19(8):849-855.doi: 10.1089/thy.2008.0419.
Supplementary files
Review
For citations:
Karalkina M.A., Vasilenko E.I., Fomin D.K., Galushko D.A. Restaging of differentiated thyroid carcinoma with SPECT/CT after radioiodine therapy. Clinical and experimental thyroidology. 2015;11(3):17-23. (In Russ.) https://doi.org/10.14341/ket2015317-23
Views:
3563
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
